Anticipated $-0.57 EPS for Sarepta Therapeutics, Inc. (SRPT) on July, 18

June 27, 2018 - By Leslie Harms

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Corporate Logo
Big Money Sentiment decreased to 0.97 in 2018 Q1. It has change of 0.25, from 2017Q4’s 1.22. The ratio is negative due to Sarepta Therapeutics, Inc. positioning: 31 sold and 81 reduced. 45 funds took positions and 64 increased positions. Investors holded 52.88 million in 2017Q4 but now own 54.74 million shares or 3.52% more.
Winslow Evans Crocker Inc holds 2,100 shs or 0% of its capital. Tiaa Cref Investment Limited Co owns 202,136 shs. Eventide Asset Lc holds 226,000 shs or 0.78% of its capital. 35 are held by Riggs Asset Managment. Tekla stated it has 1.09% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 3,963 were accumulated by Etrade Cap Mngmt Ltd. Dimensional Fund L P invested 0% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). North Carolina-based Bancorporation Of America De has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Eam Investors Ltd Liability Co has 39,980 shs. Oak Ridge Investments Ltd Liability Corp owns 131,334 shs for 0.54% of their capital. 37,696 were reported by Proshare Advsr Llc. Castleark Limited Liability stated it has 0.24% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Canada Pension Plan Inv Board stated it has 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Pinnacle Associate has 0.42% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 290,121 shs. Orbimed Ltd stated it has 321,600 shs.

On July, 18 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s earnings report is awaited by WallStreet, as reported by RTT. Analysts forecast $-0.57 EPS. That’s $0.58 up or 50.43 % from 2017’s earnings of $-1.15. Wall Street now sees 29.55 % negative EPS growth despite Sarepta Therapeutics, Inc. previous quarter’s EPS of $-0.44. The stock decreased 3.69% or $5 during the last trading session, hitting $130.53.Currently Sarepta Therapeutics, Inc. is uptrending after 197.08% change in last June 27, 2017. SRPT has also 768,120 shares volume. SRPT outperformed by 184.51% the S&P 500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

In total 20 analysts cover Sarepta Therapeutics (NASDAQ:SRPT). “Buy” rating has 18, “Sell” are 0, while 2 are “Hold”. 90% are bullish. 36 are the (NASDAQ:SRPT)’s analyst reports since January 3, 2018 according to StockzIntelligence Inc. On Tuesday, March 6 the company was maintained by Morgan Stanley. On Friday, February 9 Piper Jaffray maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating. Piper Jaffray has “Buy” rating and $60.0 target. On Wednesday, March 21 the stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Equal-Weight” rating given by Morgan Stanley. In Friday, May 11 report Barclays Capital upgraded the stock to “Overweight” rating. On Wednesday, June 20 Barclays Capital maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating. Barclays Capital has “Buy” rating and $18000 target. On Friday, May 4 the company was maintained by Credit Suisse. On Wednesday, June 20 Cowen & Co maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating. Cowen & Co has “Buy” rating and $17800 target. On Wednesday, June 20 WBB Securities maintained the shares of SRPT in report with “Buy” rating. On Wednesday, February 21 the firm has “Buy” rating given by J.P. Morgan. On Wednesday, June 20 the firm earned “Outperform” rating by Leerink Swann.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases.The company has $8.55 billion market cap. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.Currently it has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

For more Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news released recently go to: Seekingalpha.com, Nasdaq.com, Fool.com, Fool.com or Seekingalpha.com. The titles are as follows: “Sarepta Therapeutics: Chasing The Good News” released on June 21, 2018, “Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday” on June 19, 2018, “Are These 3 Red-Hot Gene Therapy Stocks Still Buys?” with a publish date: June 25, 2018, “3 Biotech Stocks That Soared This Week: Are They Buys?” and the last “Gene Therapy For Duchenne” with publication date: June 20, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: